Market Overview

The Genetic Testing Market in Europe to 2023: CAGR to Grow at 12.3% -


The "Europe
Genetic Testing Market - Segmented by Treatment Type, Diseases,
Technology, and Geography - Growth, Trends, and Forecast (2018 - 2023)"

report has been added to's

The Europe genetic testing market is expected to register a CAGR of
12.3% during the forecast period of 2018-2023.

Genetic testing has become quite prevalent in Europe over the last few
years, with recent developments in molecular medicine expected to
provide further impetus to this critical area. The integration of these
technologies into the healthcare system necessitates that their
application is implemented within a responsible framework of
accompanying measures and activities.

Growing Demand for Personalized Medicine

Personalized medicine, in which tailored therapy is made available to
patients with an understanding of the molecular basis of disease, has
become popular over the recent years. Genetic testing and genome
sequencing are two of the most important tools that are used to
understand the molecular basis of disease. European countries screen for
several genetic diseases, as early detection of these diseases can
prevent the onset of symptoms, or minimize the severity of the disease.

Genetic testing for cancer diagnosis can indicate the predisposition of
the disease in the gene, before its actual manifestation. This type of
diagnostic technique enables a person to take precautionary steps, and
avoid possible risks in the future. So with the growing demand for
personalized medicine, the genetic testing market is also expected to

The other factors, such as increased emphasis on early disease detection
and prevention and increasing application of genetic testing in
oncology, are driving the European genetic testing market.

Key Highlights

  • High Cost of Genetic Testing
  • Germany Leads the Market in Europe

Notable Developments in the Market

  • Abbott acquired Alere

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

  • 23andMe Inc.
  • Abbott Molecular
  • Ariosa Diagnostics Inc.
  • Biohelix Corporation (Wholly Owned Subsidiary of Quidel)
  • Biomerieux SA
  • Celera Corporation
  • Cepheid
  • Genentech Inc.

10. Future of the Market

For more information about this report visit

View Comments and Join the Discussion!